Annual Cash & Cash Equivalents
$2.14 B
+$315.69 M+17.33%
31 December 2023
Summary:
Novo Nordisk A/S annual cash & cash equivalents is currently $2.14 billion, with the most recent change of +$315.69 million (+17.33%) on 31 December 2023. During the last 3 years, it has risen by +$28.27 million (+1.34%). NVO annual cash & cash equivalents is now -29.66% below its all-time high of $3.04 billion, reached on 31 December 2017.NVO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$8.54 B
+$957.71 M+12.63%
30 September 2024
Summary:
Novo Nordisk A/S quarterly cash and cash equivalents is currently $8.54 billion, with the most recent change of +$957.71 million (+12.63%) on 30 September 2024. Over the past year, it has increased by +$4.27 billion (+100.04%). NVO quarterly cash and cash equivalents is now at all-time high.NVO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +17.3% | +100.0% |
| 3 y3 years | +1.3% | +85.6% |
| 5 y5 years | -10.8% | +210.7% |
NVO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +30.9% | at high | +833.6% |
| 5 y | 5 years | -10.8% | +30.9% | at high | +853.4% |
| alltime | all time | -29.7% | +1613.5% | at high | +6748.5% |
Novo Nordisk A/S Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $8.54 B(+12.6%) |
| June 2024 | - | $7.58 B(+728.9%) |
| Mar 2024 | - | $914.80 M(-57.2%) |
| Dec 2023 | $2.14 B(+17.3%) | $2.14 B(-49.9%) |
| Sept 2023 | - | $4.27 B(+35.6%) |
| June 2023 | - | $3.15 B(+44.0%) |
| Mar 2023 | - | $2.19 B(+20.1%) |
| Dec 2022 | $1.82 B(+11.6%) | $1.82 B(-51.6%) |
| Sept 2022 | - | $3.76 B(+17.7%) |
| June 2022 | - | $3.20 B(+59.0%) |
| Mar 2022 | - | $2.01 B(+23.2%) |
| Dec 2021 | $1.63 B(-22.6%) | $1.63 B(-64.5%) |
| Sept 2021 | - | $4.60 B(+18.7%) |
| June 2021 | - | $3.88 B(+332.9%) |
| Mar 2021 | - | $895.74 M(-57.5%) |
| Dec 2020 | $2.11 B(-9.1%) | $2.11 B(-47.5%) |
| Sept 2020 | - | $4.02 B(+7.1%) |
| June 2020 | - | $3.75 B(+160.2%) |
| Mar 2020 | - | $1.44 B(-37.8%) |
| Dec 2019 | $2.32 B(-3.2%) | $2.32 B(-15.6%) |
| Sept 2019 | - | $2.75 B(+24.8%) |
| June 2019 | - | $2.20 B(+61.9%) |
| Mar 2019 | - | $1.36 B(-43.2%) |
| Dec 2018 | $2.40 B(-21.1%) | $2.40 B(-6.1%) |
| Sept 2018 | - | $2.55 B(-10.6%) |
| June 2018 | - | $2.85 B(+64.2%) |
| Mar 2018 | - | $1.74 B(-42.8%) |
| Dec 2017 | $3.04 B(+14.3%) | $3.04 B(+0.3%) |
| Sept 2017 | - | $3.03 B(-7.7%) |
| June 2017 | - | $3.28 B(+36.2%) |
| Mar 2017 | - | $2.41 B(-9.4%) |
| Dec 2016 | $2.66 B(+7.2%) | $2.66 B(+21.5%) |
| Sept 2016 | - | $2.19 B(+11.1%) |
| June 2016 | - | $1.97 B(+168.8%) |
| Mar 2016 | - | $732.53 M(-70.4%) |
| Dec 2015 | $2.48 B(+5.5%) | $2.48 B(+6.1%) |
| Sept 2015 | - | $2.34 B(+31.3%) |
| June 2015 | - | $1.78 B(+105.1%) |
| Mar 2015 | - | $867.50 M(-63.1%) |
| Dec 2014 | $2.35 B(+18.4%) | $2.35 B(+13.9%) |
| Sept 2014 | - | $2.06 B(+125.5%) |
| June 2014 | - | $914.93 M(+88.2%) |
| Mar 2014 | - | $486.10 M(-75.5%) |
| Dec 2013 | $1.99 B(-3.0%) | $1.99 B(+16.4%) |
| Sept 2013 | - | $1.71 B(+21.0%) |
| June 2013 | - | $1.41 B(+14.2%) |
| Mar 2013 | - | $1.23 B(-39.7%) |
| Dec 2012 | $2.05 B(-12.4%) | $2.05 B(-12.3%) |
| Sept 2012 | - | $2.33 B(+53.8%) |
| June 2012 | - | $1.52 B(+0.6%) |
| Mar 2012 | - | $1.51 B(-35.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $2.34 B(+9.0%) | $2.34 B(-14.2%) |
| Sept 2011 | - | $2.72 B(+11.6%) |
| June 2011 | - | $2.44 B(+25.2%) |
| Mar 2011 | - | $1.95 B(-9.1%) |
| Dec 2010 | $2.14 B(-1.3%) | $2.14 B(-5.1%) |
| Sept 2010 | - | $2.26 B(+20.8%) |
| June 2010 | - | $1.87 B(+8.2%) |
| Mar 2010 | - | $1.73 B(-20.5%) |
| Dec 2009 | $2.17 B(+31.5%) | $2.17 B(+8.0%) |
| Sept 2009 | - | $2.01 B(+20.5%) |
| June 2009 | - | $1.67 B(+16.7%) |
| Mar 2009 | - | $1.43 B(-13.4%) |
| Dec 2008 | $1.65 B(+75.0%) | $1.65 B(+22.5%) |
| Sept 2008 | - | $1.35 B(+5.9%) |
| June 2008 | - | $1.27 B(+35.7%) |
| Mar 2008 | - | $938.43 M(-0.6%) |
| Dec 2007 | $944.09 M(+63.1%) | $944.09 M(+18.2%) |
| Sept 2007 | - | $798.55 M(+14.7%) |
| June 2007 | - | $696.00 M(+23.4%) |
| Mar 2007 | - | $564.00 M(-2.5%) |
| Dec 2006 | $578.67 M(+10.6%) | $578.67 M(-3.9%) |
| Sept 2006 | - | $602.00 M(+7.2%) |
| June 2006 | - | $561.53 M(+11.8%) |
| Mar 2006 | - | $502.45 M(-3.9%) |
| Dec 2005 | $523.00 M(-16.9%) | $523.00 M(-7.2%) |
| Sept 2005 | - | $563.69 M(+41.8%) |
| June 2005 | - | $397.43 M(-1.7%) |
| Mar 2005 | - | $404.23 M(-35.8%) |
| Dec 2004 | $629.38 M(+194.1%) | $629.38 M(+27.9%) |
| Sept 2004 | - | $492.11 M(+48.8%) |
| June 2004 | - | $330.64 M(+33.9%) |
| Mar 2004 | - | $246.84 M(+15.3%) |
| Dec 2003 | $214.01 M(+6.6%) | $214.01 M(+6.6%) |
| Dec 2002 | $200.83 M(+2.4%) | $200.83 M(+2.4%) |
| Dec 2001 | $196.03 M(+23.3%) | $196.03 M(+23.3%) |
| Dec 2000 | $159.01 M(-7.3%) | $159.01 M(-7.3%) |
| Dec 1999 | $171.62 M(+37.6%) | $171.62 M(+37.6%) |
| Dec 1998 | $124.70 M(-24.3%) | $124.70 M(-24.3%) |
| Dec 1997 | $164.71 M(+7.1%) | $164.71 M(+7.1%) |
| Dec 1996 | $153.76 M(-71.5%) | $153.76 M(-71.5%) |
| Dec 1995 | $540.42 M(-50.8%) | $540.42 M(-50.8%) |
| Dec 1994 | $1.10 B(+30.4%) | $1.10 B(+30.4%) |
| Dec 1993 | $842.90 M(-9.4%) | $842.90 M(-9.4%) |
| Dec 1992 | $930.22 M(-8.9%) | $930.22 M(-8.9%) |
| Dec 1991 | $1.02 B(+36.0%) | $1.02 B(+36.0%) |
| Dec 1990 | $750.32 M(+68.4%) | $750.32 M(+68.4%) |
| Dec 1989 | $445.58 M(+21.6%) | $445.58 M(+21.6%) |
| Dec 1988 | $366.29 M(+9.2%) | $366.29 M(+9.2%) |
| Dec 1987 | $335.56 M(+23.7%) | $335.56 M(+23.7%) |
| Dec 1986 | $271.32 M(+15.6%) | $271.32 M(+15.6%) |
| Dec 1985 | $234.75 M(+23.7%) | $234.75 M(+23.7%) |
| Dec 1984 | $189.82 M | $189.82 M |
FAQ
- What is Novo Nordisk A/S annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
- What is Novo Nordisk A/S quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly cash and cash equivalents year-on-year change?
What is Novo Nordisk A/S annual cash & cash equivalents?
The current annual cash & cash equivalents of NVO is $2.14 B
What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual cash & cash equivalents is $3.04 B
What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
Over the past year, NVO annual cash & cash equivalents has changed by +$315.69 M (+17.33%)
What is Novo Nordisk A/S quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVO is $8.54 B
What is the all time high quarterly cash and cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly cash and cash equivalents is $8.54 B
What is Novo Nordisk A/S quarterly cash and cash equivalents year-on-year change?
Over the past year, NVO quarterly cash and cash equivalents has changed by +$4.27 B (+100.04%)